The effect of anti-epileptic drugs on visual perception in patients with epilepsy

Brain

Volumn 119, Issue 2, 1996, Pages 539-549

  Paulus, Walter ^a   Schwarz, Guntram ^a   Steinhoff, Bernhard J ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Drug effect; Epilepsy; Psychophysics; Transmitter; Vision

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENYTOIN; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; COLOR VISION; CONTROLLED STUDY; EPILEPSY; GRATING; HUMAN; LUMINANCE; PERCEPTION; PRIORITY JOURNAL; PSYCHOPHYSICS; VISUAL DISCRIMINATION;

EID: 0029986906     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/119.2.539     Document Type: Article

References (33)

1. Ahnelt PK, Kolb H. Short-wavelength-sensitive cones: morphology and color-specific connections. In: Drum B, editor. Colour vision deficiencies XII. Dordrecht: Kluwer, 1995: 285-97
2. Aldenkamp AP, Vermeulen J. Phenytoin and carbamazepine: differential effects on cognitive function. Seizure 1995; 4: 95-104.
3. Allen DM, Cady FB. Analyzing experimental data by regression. Belmont (CA): Lifetime Learning Publications, 1982.
4. Bayer A. Retinale Funktionsstörungen bei Patienten unter antikonvulsiver Therapie [medical thesis]. Tübingen: University of Tübingen, 1991.
5. Bayer A, Zrenner E, Paulus W. Colour vision deficiencies induced by the anticonvulsants phenytoin and carbamazepine. In: Drum B, Moreland JD, Serra A, editors. Colour vision deficiencies X. Dordrecht: Kluwer, 1991: 599-604.
6. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neuroscience 1990; 13: 296-302.
7. Bodis-Wollner I, Yahr MD. Measurements of visual evoked potentials in Parkinson's disease. Brain 1978; 101: 661-71
8. Coenen AML, Konings GMLG, Aldenkamp AP, Renier WO, van Luijtelaar ELJM. Effects of chronic use of carbamazepine and valproate on cognitive processes. J Epilepsy 1995; 8: 250-4.
9. Crooks J, Kolb H. Localization of GABA, glycine, glutamate and tyrosine hydroxylase in the human retina. J Comp Neurol 1992; 315: 287-302.
10. Dacey DM. The dopaminergic amacrine cell. J Comp Neurol 1990; 301: 461-89.
11. Dacey DM, Lee BB. Physiological identification of cone inputs to HI and HII horizontal cells in macaque retina [abstract]. Invest Ophthalmol Vis Sci 1995; 36 (4 Suppl): S3.
12. Davanger S, Ottersen OP, Storm-Mathisen J. Glutamate, GABA, and glycine in the human retina: an immunocytochemical investigation. J Comp Neurol 1991; 311: 483-94.
13. DeLorenzo RJ. Phenytoin. Mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 271-82.
14. DeMonasterio FM, Schein SJK, McCrane EP. Staining of blue-sensitive cones of the macaque retina by a fluorescent dye. Science 1981; 213: 1278-81.
15. Grunert U, Martin PR, Wässle H. Immunocytochemical analysis of bipolar cells in the macaque monkey retina. J Comp Neurol 1994; 348: 607-27.
16. Haug BA, Trenkwalder C, Arden GB, Oertel WH, Paulus W. Visual thresholds to low-contrast pattern displacement, color contrast, and luminance contrast stimuli in Parkinson's disease. Mov Disord 1994; 9: 563-70.
17. Haug BA, Kolle R, Trenkwalder C, Oertel WH, Paulus W. Predominant affection of the blue cone pathway in Parkinson's disease. Brain 1995; 118: 771-8.
18. MacDonald RL, Kelly KM. Mechanisms of action of currently prescribed and newly developed antiepileptic drugs. [Review]. Epilepsia 1994; 35 Suppl 4: S41-50.
19. Mollon JD, Polden PG. An anomaly in the response of the eye to light of short wavelengths. Philos Trans R Soc Lond B Biol Sci 1977; 278: 207-40.
20. Paulus W, Kröger-Paulus A. A new concept of retinal colour coding. Vision Res 1983; 23: 529-40.
21. Paulus WM, Hömberg V, Cunningham K, Halliday AM. Colour and brightness coding in the central nervous system: theoretical aspects and visual evoked potentials to homogeneous red and green stimuli. Proc R Soc Lond B Biol Sci 1986; 227: 53-66.
22. Paulus W, Schwarz G, Werner A, Lange H, Bayer A, Hofschuster M, et al. Impairment of retinal increment thresholds in Huntington's disease. Ann Neurol 1993; 34: 574-8.
23. Pokorny J, Smith VC, Verriest G, Pinckers AJLG. Congenital and acquired color vision defects. New York: Grune & Stratton, 1979.
24. Pokorny J, Smith VC. Assessment of S-cone sensitivity. In: Drum B, editor. Colour vision deficiencies XII. Dordrecht: Kluwer, 1995: 299-308.
25. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992; 42: 887-90.
26. Reeves A, Wu S. Transient desensitization to luminance flicker in early dark adaptation [abstract]. Invest Ophthalmol Vis Sci 1995; 36 (4 Suppl): S16.
27. SAS/STAT Users Guide 6.03. Cary (NC): SAS Institute, 1988: 11-20.
28. Stiles WS. Increment thresholds and the mechanisms of colour vision. Docum Ophth 1949; 3: 138-65.
29. Tagliari M, Bodis-Wollner I, Kovanecz I, Stanzione P. Spatial frequency tuning of the monkey pattern ERG depends on D2 receptor-linked action of dopamine. Vision Res 1994; 34: 2051-7.
30. Tsukamoto Y, Masarachia P, Schein SJ, Sterling P. Gap junctions between the pedicles of macaque foveal cones. Vision Res 1992; 32: 1809-15.
31. Wässle H, Boycott BB. Functional architecture of the mammalian retina. [Review]. Physiol Rev 1991; 71: 447-80.
32. Wassle H, Chun MH. GABA-like immunoreactivity in the cat retina: light microscopy. J Comp Neurol 1989; 279: 43-54.
33. Zrenner E. Neurophysiological aspects of color vision in primates. Berlin: Springer-Verlag, 1982.